Crizanlizumab Clinical Trials
2 recruitingBiologic
Phase 41Phase 31
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Sickle Cell Disease
Novartis Pharmaceuticals315 enrolled31 locationsNCT06439082
Recruiting
Phase 4
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Sickle Cell Disease
Novartis Pharmaceuticals130 enrolled30 locationsNCT04657822